Richter syndrome (RS) describes the development of high-grade non-Hodgkin’s lymphoma (NHL) from low-grade NHL. RS isolated to the brain is very rare and has a poor prognosis. We describe the cases of high-grade large B-cell diffuse NHL in a 56-year-old male with chronic lymphocytic leukemia and in a 71-year-old female with previously unknown low-grade NHL, both with initial appearance of neurological symptoms. This report extends the literature of central nervous system RS and particularly highlights the importance of a thorough diagnostic evaluation of patients with low-grade NHL presenting with neurological symptoms.

Keywords:
Brain, Central nervous system, Chronic lymphocytic leukemia, Non-Hodgkin’s lymphoma, Relapse, Richter transformation
1.
Tsimberidou AM, Keating MJ: Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005;103:216–228.
2.
Omoti CE, Omoti AE: Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol 2008;142:709–716.
3.
Almhanna K, Wongchaowart N, Sweetenham J: Intracerebral Hodgkin’s lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest 2009;27:215–220.
4.
Lane PK, Townsend RM, Beckstead JH, Corash L: Central nervous system involvement in a patient with chronic lymphocytic leukemia and non-Hodgkin’s lymphoma (Richter’s syndrome), with concordant cell surface immunoglobulin isotypic and immunophenotypic markers. Am J Clin Pathol 1988;89:254–259.
5.
Robertson LE, Pugh W, O’Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ: Richter’s syndrome: a report on 39 patients. J Clin Oncol 1993;11:1985–1989.
6.
Schmid C, Diem H, Herrmann K, Voltz R, Ott G, Hallek M: Unusual sites of malignancies: Cas 2 – central neurogenic hyperventilation as a complication of Richter’s syndrome. J Clin Oncol 2005;23:2096–2098.
7.
Graves TD, Collins GP, Parry A: Richter’s syndrome of the brain and the spinal cord. J Neurol Neurosurg Psychiatry 2010;82:943–944.
8.
Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, Schmidt-Wolf IG, Schlegel U: Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009;91:299–305.
9.
Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf IG, Schlegel U: Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol 2010, E-pub ahead of print.
10.
Mahe B, Moreau P, Bonnemain B, Letortorec S, Menegali D, Bourdin S, De Lajartre D, Harousseau JL: Isolated Richter’s syndrome of the brain: two recent cases. Nouv Rev Fr Hematol 1994;36:383–385.
11.
O’Neill BP, Habermann TM, Banks PM, O’Fallon JR, Earle JD: Primary central nervous system lymphoma as a variant of Richter’s syndrome in two patients with chronic lymphocytic leukemia. Cancer 1989;64:1296–1300.
12.
Yee KW, O’Brien SM, Giles FJ: Richter’s syndrome: biology and therapy. Cancer J 2005;11:161–174.
13.
Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, Trevor J, Glaser MG, Lantos P, Ironside JW, Moss TH, Brada M, Whaley JB, Stenning SP: A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000;89:1359–1370.
14.
Ghofrani M, Tantiwongkosi B, Smith AS, Wasdahl DA: Richter transformation of chronic lymphocytic leukemia presenting as a dural-based non-hodgkin lymphoma mass. AJNR Am J Neuroradiol 2007;28:318–320.
15.
Patrij K, Reiser M, Watzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG: Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci 9:Doc11.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.